TB Alliance Licenses Late-stage TB Program to CSIR-OSDD
TB Alliance, an international non-profit organization which develops better, faster-acting, and affordable TB drugs, has announced that it has granted
TB Alliance, an international non-profit organization which develops better, faster-acting, and affordable TB drugs, has announced that it has granted
Over the past year, the pursuit of new TB drugs has seen incredible progress. Positive results of first regimen trial
In spite of an estimated 500,000 new annual cases of children with tuberculosis (TB), there are no appropriate medicines for
TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to
TB Alliance announces new leadership of its Stakeholders Association (SHA), an advisory group comprised of member organizations that share a
TB Alliance, a not-for-profit organization with the mission of developing new, improved, and affordable TB treatments, announces the election of
The phase 2b clinical trial of the TB vaccine candidate MVA85A is historic, the first efficacy study of a novel
Pyrazinamide (PZA) is an incredibly important sterilizing agent in the treatment of tuberculosis and is considered responsible for reducing the
The Global Alliance for TB Drug Development (TB Alliance) is pleased to announce the appointment of Dr. Carlos Morel to
The US FDA approval of bedaquiline is historic, as it marks the first drug in a new class approved to